CNMD Conmed

CONMED Corp. operates as a medical technology company, which engages in the development, manufacture and sale of surgical devices and related equipment. It operates through the following geographical segments: United States; Americas excluding the United States; Europe, Middle East, and Africa; and Asia Pacific. Its product lines also include orthopedic surgey and general surgery. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Utica, NY.

Company profile

Curt Hartman
Fiscal year end
IRS number

CNMD stock data



22 Feb 21
17 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Conmed earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 27.36M 27.36M 27.36M 27.36M 27.36M 27.36M
Cash burn (monthly) 2.75M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 9.82M n/a n/a n/a n/a n/a
Cash remaining 17.54M n/a n/a n/a n/a n/a
Runway (months of cash) 6.4 n/a n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
31 Mar 21 Heather L Cohen Common Stock Grant Aquire A No No 124.06 191 23.7K 24,456
31 Mar 21 Daniel Jonas Common Stock Grant Aquire A No No 124.06 43 5.33K 13,806
31 Mar 21 Todd W. Garner Common Stock Grant Aquire A No No 124.06 191 23.7K 6,201
1 Mar 21 Terence M Berge Common Stock Sell Dispose S No No 122.5 2,550 312.38K 1,004
1 Mar 21 Terence M Berge Common Stock Option exercise Aquire M No No 97.69 2,550 249.11K 3,554
1 Mar 21 Terence M Berge Common Stock Sell Dispose S No No 122.5 5,400 661.5K 1,004
1 Mar 21 Terence M Berge Common Stock Option exercise Aquire M No No 78.76 5,400 425.3K 6,404
1 Mar 21 Terence M Berge Common Stock Sell Dispose S No No 122.5 2,700 330.75K 1,004
1 Mar 21 Terence M Berge Common Stock Option exercise Aquire M No No 59.96 2,700 161.89K 3,704
1 Mar 21 Terence M Berge Common Stock Sell Dispose S No No 122.5267 2,800 343.07K 1,004

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 246 239 +2.9%
Opened positions 40 41 -2.4%
Closed positions 33 28 +17.9%
Increased positions 94 69 +36.2%
Reduced positions 76 90 -15.6%
13F shares
Current Prev Q Change
Total value 3.45B 2.36B +46.2%
Total shares 30.82M 30.03M +2.6%
Total puts 84.7K 45.2K +87.4%
Total calls 27.8K 74.8K -62.8%
Total put/call ratio 3.0 0.6 +404.2%
Largest owners
Shares Value Change
BLK Blackrock 4.48M $501.52M +5.1%
Vanguard 3M $336.27M +2.8%
Champlain Investment Partners 1.69M $189.51M +8.0%
Earnest Partners 1.58M $176.44M +41.1%
STT State Street 972.44K $109.1M +2.8%
Dimensional Fund Advisors 963.73K $107.94M -5.5%
IVZ Invesco 930.26K $104.19M -1.5%
PFG Principal Financial Group Inc - Registered Shares 916.93K $102.7M -9.8%
MCQEF Macquarie 775.72K $86.88M +3.4%
Capital Research Global Investors 718.3K $80.45M +3.4%
Largest transactions
Shares Bought/sold Change
Point72 Asset Management 58.56K -788.98K -93.1%
Earnest Partners 1.58M +459.19K +41.1%
Scopia Capital Management 310.39K -336.8K -52.0%
Norges Bank 271.14K +271.14K NEW
Loomis Sayles & Co L P 295.5K +227.22K +332.8%
BLK Blackrock 4.48M +216.63K +5.1%
Eagle Asset Management 649.35K +194.62K +42.8%
Peregrine Capital Management 184.72K +184.72K NEW
Carillon Tower Advisers 334.49K +166.67K +99.3%
Iron Triangle Partners 148.32K +148.32K NEW

Financial report summary

  • Our financial performance is dependent on conditions in the healthcare industry and the broader economy.
  • The COVID-19 global pandemic may pose significant risks to our business if the pandemic, and various government responses to it, continue for an extended period of time.
  • As a manufacturer of medical devices that interacts with physicians and health care providers domestically and internationally, we face risks under domestic and foreign regulations, including the Foreign Corrupt Practices Act.
  • The highly competitive market for our products may create adverse pricing pressures.
  • Cost reduction efforts in the healthcare industry could put pressures on our prices and margins.
  • We may not be able to keep pace with technological change or to successfully develop new products with wide market acceptance, which could cause us to lose business to competitors.
  • Our variable rate indebtedness subjects us to interest rate risk, which could cause our debt service obligations to increase significantly.
  • Our interest rates may be impacted by the phase out of LIBOR.
  • The convertible notes hedge and warrant transactions that we entered into in connection with the offering of the Convertible Notes may affect the value of the Convertible Notes and our common stock.
  • We are subject to counterparty risk with respect to the convertible notes hedge transactions.
  • The terms of any future preferred equity or debt financing may give holders of any preferred securities or debt securities rights that are senior to rights of our common shareholders or impose more stringent operating restrictions on our company.
  • We could experience a failure of a key information technology system, process or site or a breach of information security, including a cybersecurity breach or failure of one or more key information technology systems, networks, processes, associated sites or service providers, and could potentially become liable for a breach of various data privacy regulations.
  • We rely on a third party to obtain, process and distribute sports medicine allograft tissue. If such tissue cannot be obtained, is not accepted by the market or is not accepted under numerous government regulations, our results of operations could be negatively impacted.
  • We distribute some products for third-party companies, and cannot ensure that our rights to distribute such third-party products will continue indefinitely.
  • If we lose our patents or they are held to be invalid, or if our products or services infringe on third party patents, we could become subject to liability and our competitive position could be harmed.
  • Damage to our physical properties as a result of windstorm, earthquake, fire or other natural or man-made disaster may cause a financial loss and a loss of customers.
  • Our new products may fail to achieve expected levels of market acceptance.
Content analysis
H.S. sophomore Avg
New words: abnormally, accuracy, Addison, Additionally, administered, aging, agreed, Aid, ambulatory, Anchor, Anthrex, autoclavable, belief, bench, borne, broadest, broadly, California, cleaning, closure, conserved, COVID, culture, cutting, deferral, depressed, depression, desired, discovered, discreet, distancing, duration, EEG, EU, exculpation, faster, floor, footnote, formal, forum, governmental, grid, half, heightened, hygiene, ICO, imperative, importantly, Incheon, intentionally, job, light, maximum, MDD, MDR, methodology, MicroFree, moving, NYSE, pandemic, passed, people, population, postponed, prolonged, proper, question, rationalization, rebound, rebounding, recapitalization, recession, recruiting, recruitment, remotely, residual, resurgence, rounded, Seoul, sequential, show, slightly, social, South, spread, stimulate, stricter, subsided, surveillance, taxpayer, threatened, TitanTM, track, tracking, trademark, travel, tuition, turnover, uncertain, undertaken, underutilization, visibility, voluntary, wake, weakened, winding, written
Removed: anticipating, application, arthroplasty, arthroscopy, chairman, compensatory, eligible, enactment, excise, expensing, Headquartered, imposed, impossible, limitation, Luke, modularity, mortgage, Nemo, neurosurgery, onsite, pacing, Pomilio, preliminary, Prime, punitive, repeal, room, simplify, stoppage, SurgiQuest, transparency, trauma, unvested, verdict, versatility


Sheathed Surgical Saw Blade with Bearings
8 Apr 21
A sheathed blade assembly for minimizing or preventing contact between the moving interior blade and the exterior sheath.
Single lumen gas sealed trocar for maintaining stable cavity pressure without allowing instrument access therethrough during endoscopic surgical procedures
6 Apr 21
A system for performing an endoscopic surgical procedure in a surgical cavity of a patient that includes a multi-lumen tube set including a dual lumen portion having a pressurized gas line and a return gas line for facilitating gas recirculation relative to the surgical cavity of the patient, and a single lumen portion having a gas supply and sensing line for delivering insufflation gas to the surgical cavity of the patient and for periodically sensing pressure within the surgical cavity of the patient, a first gas sealed single lumen access port communicating with the dual lumen portion of the tube set and a second valve sealed single lumen access port communicating with the single lumen portion of the tube set.
Endoscopic Visualization System
1 Apr 21
An endoscopic visualization system (10) includes an endoscopic subsystem (26) comprising an endoscope having an optical channel and an illumination channel, an image sensor operatively coupled to receive light from the optical channel and a solid-state light source operatively coupled to transmit light through the illumination channel; at least one electrical cable extending from the endoscopic subsystem; and a monitor subsystem (12) comprising a frame defining an inner compartment, a display screen and at least one port configured to receive the at least one electrical cable connected to the endoscopic subsystem.
System and method for securing tissue to bone
30 Mar 21
Disclosed herein are methods and devices for securing soft tissue to a rigid material such as bone.
Cannulated Tissue Needle with Suture Grasping Mechanism
25 Mar 21
A suture passer for use in arthroscopic soft tissue repair procedures.